Intravenous igg to prevent graft-versus-host disease after bone marrow transplantation

Thomas C. Bailey, John R. Wingard, Georgia Vogelsang, Steven Piantadosi, Keith M. Sullivan, Kenneth J. Kopecky, C. Dean Buckner, Rainer Storb

Research output: Contribution to journalLetter

2 Scopus citations

Abstract

Sullivan et al. (Sept. 13 issue)1 report that the administration of intravenous immunoglobulin to patients undergoing bone marrow transplantation had beneficial effects with respect to the amelioration of graft-versus-host disease, interstitial pneumonitis, and infections. However, caution is warranted in the light of the cost of the immunoglobulin regimen described. Hospital pharmacies typically charge patients a fixed percentage above the “average wholesale price” of a given pharmaceutical agent, although the average wholesale price does not necessarily reflect the acquisition cost of the drug. The average wholesale price for the drug used in the study, Gamimune N, is 285.60 …

Original languageEnglish
Pages (from-to)631-633
Number of pages3
JournalNew England Journal of Medicine
Volume324
Issue number9
DOIs
StatePublished - Feb 28 1991

Fingerprint Dive into the research topics of 'Intravenous igg to prevent graft-versus-host disease after bone marrow transplantation'. Together they form a unique fingerprint.

  • Cite this

    Bailey, T. C., Wingard, J. R., Vogelsang, G., Piantadosi, S., Sullivan, K. M., Kopecky, K. J., Buckner, C. D., & Storb, R. (1991). Intravenous igg to prevent graft-versus-host disease after bone marrow transplantation. New England Journal of Medicine, 324(9), 631-633. https://doi.org/10.1056/NEJM199102283240912